Syndax Announces Participation in February Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its participation in two upcoming investor conferences in February 2025. CEO Michael A. Metzger and the management team will attend:
1. The Guggenheim SMID Cap Biotech Conference in New York, featuring a fireside chat on February 6, 2025, at 10:30 a.m. ET
2. Citi's 2025 Virtual Oncology Leadership Summit, with a fireside chat scheduled for February 19, 2025, at 9:00 a.m. ET
Both presentations will be available via webcast on the company's website investor section, with replays accessible for a time.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was -0.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Guggenheim SMID Cap Biotech Conference in
New York, NY with a fireside chat on Thursday, February 6, 2025, at 10:30 a.m. ET - Citi's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025, at 9:00 a.m. ET
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-in-february-investor-conferences-302363686.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.